Curapel Overview
- Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.96M
- Investors
-
6
Curapel General Information
Description
Developer of specialty pharmaceutical products intended for the treatment of common skin conditions. The company's healthcare process develops oral and cream-based medicinal products for the treatment of conditions like skin pigmentation, eczema, atopic dermatitis, lightening and psoriasis, enabling the medical community and patients to meet and resolve unmet clinical needs.
Contact Information
Website
www.curapel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Personal Products
Drug Discovery
Primary Office
- Stuart House
- Chepstow NP16 5HH
- Wales, United Kingdom
+44 07866 000000
Curapel Timeline
Curapel Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 01-May-2021 | $1.96M | 00.000 | Completed | Generating Revenue | |
| 6. Later Stage VC | 01-Mar-2020 | 00000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 5. Angel (individual) | 05-Sep-2017 | 00000 | 00.000 | 00.000 | Completed | Startup |
| 4. Grant | 01-May-2017 | 00000 | 00000 | Completed | Generating Revenue | |
| 3. Angel (individual) | 15-Aug-2016 | 00000 | 00000 | 00.000 | Completed | Startup |
| 2. Angel (individual) | 14-Jun-2014 | $336K | $336K | 00.000 | Completed | Startup |
| 1. Grant | $36.2K | Completed | Startup |
Curapel Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Preferred Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Preferred Ordinary | 2,333,333 | $0.012974 | $0.19 | $0.19 | 1x | $0.19 | 12.06% | |
| Ordinary | 2,353,329 | $0.000013 | $0.19 | $0.19 | 1x | $0.19 | 12.17% |
Curapel Patents
Curapel Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2875275-T3 | Exothermic topical devices for the delivery of drugs and cosmetics to the skin | Active | 30-Nov-2015 | 0000000000 | |
| GB-2544813-A | Devices and methods for delivering pharmaceuticals and cosmetics to the skin | Granted | 30-Nov-2015 | 0000000000 | 0 |
| EP-3413867-A1 | Exothermic topical devices for delivering pharmaceuticals and cosmetics to the skin | Granted | 30-Nov-2015 | 0000000000 | |
| GB-201521111-D0 | Devices and methods for delivering pharmaceuticals and cosmetics to the skin | Granted | 30-Nov-2015 | 0000000000 | |
| US-20180353438-A1 | Exothermic topical devices for delivering pharmaceuticals and cosmetics to the skin | Abandoned | 30-Nov-2015 | A61K9/7092 |
Curapel Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Peter Luebcke Ph.D | Chief Executive Officer | ||
| Neil Gibbs Ph.D | Co-Founder, Chief Scientific Officer & Board Member | ||
| Alan Williams | Finance Director |
Curapel Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Neil Gibbs Ph.D | Curapel | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
| Terry Sadler | Self | Chairman | 000 0000 |
Curapel Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Development Bank of Wales | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Meltwind | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Innovate UK | Government | 000 0000 | 000000 0 | ||
| Lancaster Capital | Angel Group | Minority | 000 0000 | 000000 0 | |
| Biotechnology and Biological Science Research Council | Limited Partner | 000 0000 | 000000 0 |